Press releases
September 8, 2021
Eirion Therapeutics Announces Strategic Agreement
As part of the agreement, HTL will build, validate and operate a botulinum manufacturing facility in the US. In the future, HTL Biotechnology expects to apply to the CDC to have the facility certified to manufacture botulinum and later apply to the FDA to have it certified as a GMP plant.
Read more below.
To see our most recent news,
Read more
news from us
-
Articles October 3, 2024HTL Biotechnology will launch its White Paper at CPHI Milan!
We are excited to announce that the HTL Biotechnology team will be attending CPHI Milan and on this occasion, we will be launching our White Paper to celebrate 90 years of discovery of Hyaluronic Acid!
-
Articles October 1, 2024New Certification for HTL Biotechnology
We are proud to announce that HTL Biotechnology has recently received Halal certification for two of our key products: DNA and HANa.
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.